Categories: Business NewsHealthcareNewsPharmaceutical

ARA Launches Innovative SoftVue Breast Cancer Screening

Women participating in the SoftVue breast cancer screening program at ARA in Cedar Park.

Article Sponsored by:

SPACE AVAILABLE FOR SPONSORS!

Want to target the right audience? Sponsor our site and choose your specific industry to connect with a relevant audience.

What Sponsors Receive:

Prominent brand mentions across targeted, industry-focused articles
High-visibility placements that speak directly to an engaged local audience
Guaranteed coverage that maximizes exposure and reinforces your brand presence

Interested in seeing what sponsored content looks like on our platform?

Browse Examples of Sponsored News and Articles:

May’s Roofing & Contracting
Forwal Construction
NSC Clips
Real Internet Sales
Suited
Florida4Golf

Click the button below to sponsor our articles:

Sponsor Our Articles

News Summary

In Cedar Park, Texas, the Austin Radiological Association (ARA) has launched the SoftVue breast cancer screening program, designed to improve detection for women with dense breast tissue. This FDA-approved system, introduced in December 2024, complements traditional mammograms and aims to enhance early detection rates, especially for women at risk. With a focus on patient comfort, SoftVue offers a more convenient, radiation-free alternative to standard mammograms, showcasing ARA’s commitment to advancing breast health care in the community.

Exciting News from Cedar Park: ARA Launches Innovative SoftVue Breast Cancer Screening

In Cedar Park, Texas, health care is getting a major upgrade! The Austin Radiological Association (ARA), in partnership with Delphinus Medical Technologies, has kicked off a groundbreaking breast cancer screening program that promises to change the way women think about breast health. Launched in December 2024 at ARA’s Cedar Park location, the SoftVue screening program has already garnered attention for its remarkable benefits.

What is SoftVue?

SoftVue is not just your everyday ultrasound. It is the only FDA-approved breast ultrasound tomography system designed specifically for supplemental screening in women who might be at risk due to dense breast tissue. For those who may not know, about 40% of women in the U.S. have dense breast tissue, which can make it trickier to detect cancer early. This is crucial because dense breast tissue not only complicates the imaging process but also heightens the risk of breast cancer.

How Does SoftVue Work?

The magic of SoftVue lies in its ability to work alongside traditional mammograms. Clinical studies have shown that when SoftVue is used in combination with mammography, it can detect 25% more cancers than mammography alone, especially in women with dense breast tissue. What a win for early detection!

The process is also notably comfortable! Unlike traditional mammograms, the SoftVue exam doesn’t require any harmful compression or radiation. Women can even undergo the SoftVue exam during the same visit as their standard mammogram, making it a convenient option for those seeking thorough breast health evaluations.

Enhancing Patient Care

With the integration of SoftVue, ARA is stepping up the game significantly in patient care and satisfaction. By offering this reimbursable supplementary screening option, they aim to provide the best possible services for their patients. Not only does this align with the latest Mammography Quality Standards Act (MQSA) guidelines, but it also emphasizes ARA’s commitment to innovative and effective healthcare practices.

Building a Better Future in Breast Health

The leadership at ARA recognizes the importance of advancing imaging technology. Their proactive approach to integrating SoftVue highlights a focus on patient comfort and improved compliance rates. With a team of over 115 board-certified radiologists, ARA has been a cornerstone of diagnostic imaging in Austin since 1954, specializing in varied fields to cater to community health needs.

Meanwhile, Delphinus Medical Technologies is doing its part by revolutionizing the way breast cancer is detected. With headquarters in Novi, Michigan, this company has made a name for itself via its patented circular array transducer technology, aiming to save lives by enhancing early detection methods.

Looking Ahead

As the SoftVue program continues to grow, experts point to its potential positive outcomes for women’s health. By expanding access to these innovative technologies, ARA and Delphinus are making strides towards a future where early detection of breast cancer is a norm rather than an exception. For many women, this means greater peace of mind and the possibility of catching potential health issues sooner than ever before.

With partnerships like these and technologies like SoftVue, the landscape of breast cancer screening is transforming in Cedar Park, providing hope and healthier tomorrows for women everywhere.